Target intelligence / Profile preview

Complement system components (C3 and C4) (Complement)

Target
Complement
Molecular classification
Plasma protein, Complement protein, Immune system component
01

Overview

The complement system consists of a series of plasma proteins that play a critical role in the innate immune response and inflammation. In many autoimmune and inflammatory diseases, overactivation of the complement cascade leads to tissue damage through opsonization and the formation of the membrane attack complex. Intravenous immunoglobulin (IVIG) acts as a therapeutic modulator by interacting directly with various complement components. Specifically, IVIG can scavenge active fragments such as C3b and C4b via its Fab and Fc regions, effectively neutralizing their pro-inflammatory effects (Basta et al., 2003). This interaction prevents the amplification of the complement cascade and protects host cells from complement-mediated destruction (Lutz et al., 2004). Consequently, IVIG is a vital treatment for conditions like Myasthenia Gravis and Guillain-Barré syndrome where complement-mediated injury is a primary driver of pathology (StatPearls, 2023). Monitoring serum C3 and C4 levels can help assess the efficacy of IVIG in modulating the complement system during treatment.

Other names
C3C4C1qComplement cascadeComplement proteins
02

Mechanism of action

IVIG interacts with complement components through both its Fab and Fc regions. The Fab fragments can specifically bind to and neutralize active complement fragments like C3b and C4b, preventing their deposition on host tissues and the subsequent formation of the membrane attack complex. Additionally, the Fc portion of IVIG can bind to C1q, diverting it from its normal targets and thereby inhibiting the initiation of the classical complement pathway.

03

Biological functions

Immune responseInflammationOpsonizationCell lysis
04

Disease associations

Autoimmune diseaseInflammationSystemic lupus erythematosusMyasthenia gravisGuillain-Barre syndrome
05

Safety considerations

Infusion-related reactionsThrombotic eventsRenal dysfunctionAseptic meningitis
06

Interacting drugs

Intravenous immunoglobulin (IVIG)

1 more in the full profile.

07

Biomarkers

Serum C3 levelsSerum C4 levelsCH50 (Total Hemolytic Complement)C3d deposition

Beyond the preview

Go deeper on Complement system components (C3 and C4) (Complement).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Complement system components (C3 and C4) (Complement).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call